UNSPSC 51432406: Moveltipril calcium

This classification denotes an ace inhibitor with the molecular formula 2C19H29N2O5S.Ca, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier SB44S25HE5, chemically known as l-proline, n-(cyclohexylcarbonyl)-d-alanyl-(2s)-3-mercapto-2-methylpropanoyl-, calcium salt (2:1), but more generally known as moveltipril calcium, which bears US NIH Compound Identifier 6336573. European Medicines Agency schedules moveltipril calcium or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09078MIG.

Most nations, for tariff purposes, schedule moveltipril calcium under HS 29339990. SMILES: C[C@H](CSC(=O)[C@@H](C)NC(=O)C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)[O-].C[C@H](CSC(=O)[C@@H](C)NC(=O)C1CCCCC1)C(=O)N2CCC[C@H]2C(=O)[O-].[CA+2].

UNSPSC 51432406 Moveltipril calcium is a Commodity code that encompasses individual pharmaceutical active ingredients and finished-dose medications procured by state and local health agencies, fire rescue departments, and pharmacy benefit programs. Recent state and local solicitations under this code show governments buying advanced life support medications, generic pharmaceuticals, and over-the-counter products for distribution through emergency services and state health benefit systems. The City of Tampa's Fire Rescue procurement exemplifies the emergency-medicine use case, while the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) and Texas Health and Human Services Commission represent larger-scale pharmacy benefit and multi-jurisdictional distribution models. Issuing bodies range from municipal fire departments and city procurement offices to state health agencies and cooperative purchasing alliances serving multiple states and localities.

Activity concentrates in Florida, Minnesota (serving participating states including Oregon), and Texas, with procurement spanning traditional sealed-bid awards to exploratory requests for information. The City of Tampa issued an IFB (Bid No. 26P00188) in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem, with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00; the award included a 5 percent SLBE bid discount. MMCAP issued an RFP (S1070000015802) with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (Cencora, Cardinal Health, and Morris & Dickson) and available to member jurisdictions beginning July 1, 2026. The Texas HHS Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager arrangements, signaling early-stage exploration of alternative pharmacy supply models without disclosed budget or award timeline.